|
|
|
(C) Vancouver
General Hospital.
This monograph may not be reproduced without permission.
For further information, please contact a Pharmacist. |
NAME OF DRUG
ceftazidime pentahydrate
CLASSIFICATION
Cephalosporin antibiotic
(RESERVED ANTIMICROBIAL DRUG)
ALTERNATE NAME
FORTAZ, MAGNACEF, TAZIDIME
INDICATIONS
- treatment of systemic infections caused by susceptible strains of micro-organisms
as approved by the Antibiotic Utilization Subcommittee
RECONSTITUTION AND STABILITY
- powder stable at room temperature, protect powder from light
- reconstitute with sterile water for injection
- add 3 mL diluent to 1 g vials to provide a concentration of 280 mg/mL (for IM, IV
use)
- add 10 mL diluent to 2 g vials to provide a concentration of 180 mg/mL (for IV use)
- reconstituted solution should not be stored for more than 24 hours in the
refrigerator
COMPATIBILITY
- compatible with commonly used IV solutions
- DO NOT mix with any other drug in the same container
-
compatible
via Y-site with acyclovir, aminophylline, cefazolin, cefuroxime,
ciprofloxacin, clindamycin, heparin,
labetalol, meperidine, metronidazole, morphine, multivitamins, ondansetron,
potassium chloride, ranitidine
-
incompatible
with aminoglycosides, vancomycin
ROUTES OF ADMINISTRATION
- IM - deeply into muscle
- IV direct - dilute to 10 mL with compatible IV solution and administer over 3-5
minutes
- IV intermittent - in 50 mL of IV solution and administer over 15-30 minutes
- give dose post
dialysis in hemodialysis patients
VH & HSC ADMINISTRATION POLICY
E - Direct IV route can be administered by nurses on general nursing units provided
that a venous access has been established and according to policies and recommendations
stated in this manual
DOSAGE
- Adults: Life-threatening infections - 6 g/day in 3 equally divided doses given every 8
hours
- Children: 2 months to 12 years - 100-150 mg/kg/24 hours (max 6 g/day) divided every
eight hours
Note: Dosage adjustments are necessary based on creatinine clearance
|
Creatinine Clearance |
Dosage |
|
30-50 mL/min |
1-2 g q12h |
|
< 30 mL/min |
1-2 g q12-24h |
|
Hemodialysis |
1-2 g DAD* or 0.5-1 g q24h DAD* |
|
CAPD |
0.5-1 g q24h |
|
DAD* = give dose after dialysis (on hemodialysis
days) |
POTENTIAL HAZARDS OF PARENTERAL ADMINISTRATION
- thrombophlebitis at IV site
- pain and tenderness at IM injection site
- hypersensitivity reactions
IMPORTANT IMPLICATIONS
- contraindicated in patients with known hypersensitivity to cephalosporins
- caution in patients with hypersensitivity to penicillins
- 1 gram of ceftazidime contains 2.3 mEq of sodium
- may cause a false-positive urine glucose with clinitest; use Clinistix or Tes-tape if
urinary glucose is being monitored
Rev. May 2008